Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDAon October 8, 2020 at 5:10 pm
PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ...
- Meta-Analysis Backs MRD as AML Trial Endpointon October 8, 2020 at 12:15 pm
Reaching measurable residual disease (MRD) negativity in acute myeloid leukemia (AML) was associated with improved survival outcomes and could be used as an endpoint to speed up trials of novel ...
- Oncology biotech Kronos Bio increases deal size by 28% ahead of $224 million IPOon October 8, 2020 at 6:12 am
The article Oncology biotech Kronos Bio increases deal size by 28% ahead of $224 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
- Hemogenyx Pharmaceuticals PLC Announces SAFE-HEMO-CAR-T Effective against AML in vitroon October 5, 2020 at 11:00 pm
LONDON, UK / ACCESSWIRE / October 6, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the ...
- A Uniquely Patient-Focused Take on Treating AML in Older Adultson October 5, 2020 at 1:55 pm
Dr Mikkael Sekeres discusses how the recent ASH guidelines, on which he is a coauthor, are meant to guide the difficult decisions that follow a new diagnosis of AML in older patients.
- Kronos Bio Seeks $175 Million IPO For AML And Solid Tumor Treatmentson October 5, 2020 at 12:43 pm
Kronos Bio has filed proposed terms for a $175 million U.S. IPO. The firm is advancing a pipeline of treatment candidates for acute myeloid leukemia [AML] and solid tumors. KRON has shown intriguing ...
- Jazz amplifies info in crowded AML space with new online education centeron October 5, 2020 at 5:30 am
Jazz Pharmaceuticals launched “Find the Right Fit” to highlight two rare blood cancer types—myelodysplastic syndrome and secondary acute myeloid leukemia. The campaign, created in partnership with two ...
- Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran.on October 4, 2020 at 10:13 pm
Although patients with severe immunodeficiency and hematological malignancies has been considered at highest risk for invasive fungal infection, patients with severe pneumonia due to influenza, and ...
- New oral treatment option for aggressive blood cancer, AMLon October 2, 2020 at 2:38 pm
WAUSAU, Wis. (WSAW) - September was Blood Cancer Awareness Month, a time to recognize and raise awareness for this diverse group of diseases, including acute myeloid leukemia, or AML, which is one of ...
- New Brave Fellowship powers Dr. Alyssa Webster’s race for new leukemia cureson September 30, 2020 at 9:22 am
Running helps Dr. Alyssa Webster to think through scientific challenges. Now, with her new Brave Fellowship, running is helping fuel her science by funding her research on leukemia.
via Bing News